479 related articles for article (PubMed ID: 37296584)
1. Epidrugs in the Therapy of Central Nervous System Disorders: A Way to Drive on?
Gladkova MG; Leidmaa E; Anderzhanova EA
Cells; 2023 May; 12(11):. PubMed ID: 37296584
[TBL] [Abstract][Full Text] [Related]
2. Perspectives and new aspects of histone deacetylase inhibitors in the therapy of CNS diseases.
Han B; Wang M; Li J; Chen Q; Sun N; Yang X; Zhang Q
Eur J Med Chem; 2023 Oct; 258():115613. PubMed ID: 37399711
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Regulation in Breast Cancer: Insights on Epidrugs.
Kim A; Mo K; Kwon H; Choe S; Park M; Kwak W; Yoon H
Epigenomes; 2023 Feb; 7(1):. PubMed ID: 36810560
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases.
Qiu X; Xiao X; Li N; Li Y
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jan; 72():60-72. PubMed ID: 27614213
[TBL] [Abstract][Full Text] [Related]
5. Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis.
Citraro R; Leo A; Santoro M; D'agostino G; Constanti A; Russo E
Curr Pharm Des; 2017; 23(37):5546-5562. PubMed ID: 29076408
[TBL] [Abstract][Full Text] [Related]
6. Epigenetics in Neurodegenerative Diseases: The Role of Histone Deacetylases.
Sharma S; Sarathlal KC; Taliyan R
CNS Neurol Disord Drug Targets; 2019; 18(1):11-18. PubMed ID: 30289079
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders.
Abel T; Zukin RS
Curr Opin Pharmacol; 2008 Feb; 8(1):57-64. PubMed ID: 18206423
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities.
Rodrigues DA; Pinheiro PSM; Sagrillo FS; Bolognesi ML; Fraga CAM
Med Res Rev; 2020 Nov; 40(6):2177-2211. PubMed ID: 32588916
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial biogenesis: pharmacological approaches.
Valero T
Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
[TBL] [Abstract][Full Text] [Related]
10. Creating zinc monkey wrenches in the treatment of epigenetic disorders.
Kalin JH; Butler KV; Kozikowski AP
Curr Opin Chem Biol; 2009 Jun; 13(3):263-71. PubMed ID: 19541531
[TBL] [Abstract][Full Text] [Related]
11. An overview of vitamins as epidrugs for colorectal cancer prevention.
Boughanem H; Kompella P; Tinahones FJ; Macias-Gonzalez M
Nutr Rev; 2023 Mar; 81(4):455-479. PubMed ID: 36018754
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies.
Urdinguio RG; Sanchez-Mut JV; Esteller M
Lancet Neurol; 2009 Nov; 8(11):1056-72. PubMed ID: 19833297
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic Basis of Lead-Induced Neurological Disorders.
Wang T; Zhang J; Xu Y
Int J Environ Res Public Health; 2020 Jul; 17(13):. PubMed ID: 32645824
[TBL] [Abstract][Full Text] [Related]
14. Promising Molecular Targets for Pharmacological Therapy of Neurodegenerative Pathologies.
Neganova ME; Aleksandrova YR; Nebogatikov VO; Klochkov SG; Ustyugov AA
Acta Naturae; 2020; 12(3):60-80. PubMed ID: 33173597
[TBL] [Abstract][Full Text] [Related]
15. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.
Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J
Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171
[TBL] [Abstract][Full Text] [Related]
16. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
Levite M
J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological potential of JWH133, a cannabinoid type 2 receptor agonist in neurodegenerative, neurodevelopmental and neuropsychiatric diseases.
Hashiesh HM; Jha NK; Sharma C; Gupta PK; Jha SK; Patil CR; Goyal SN; Ojha SK
Eur J Pharmacol; 2021 Oct; 909():174398. PubMed ID: 34332924
[TBL] [Abstract][Full Text] [Related]
18. Epidrugs as Promising Tools to Eliminate
Reyser T; Paloque L; Nguyen M; Augereau JM; Fuchter MJ; Lopez M; Arimondo PB; Hassell-Hart S; Spencer J; Di Stefano L; Benoit-Vical F
Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896200
[TBL] [Abstract][Full Text] [Related]
19. HDAC modulation and cell death in the clinic.
Dell'Aversana C; Lepore I; Altucci L
Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitors and neurodegeneration: at the edge between protection and damage.
Dietz KC; Casaccia P
Pharmacol Res; 2010 Jul; 62(1):11-7. PubMed ID: 20123018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
